387 related articles for article (PubMed ID: 34021591)
1. Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.
Spagnolo F; Boutros A; Croce E; Cecchi F; Arecco L; Tanda E; Pronzato P; Lambertini M
Eur J Clin Invest; 2021 Jul; 51(7):e13604. PubMed ID: 34021591
[TBL] [Abstract][Full Text] [Related]
2. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2).
Bersanelli M; Giannarelli D; De Giorgi U; Pignata S; Di Maio M; Clemente A; Verzoni E; Giusti R; Di Napoli M; Aprile G; Ermacora P; Catino A; Scotti V; Mazzoni F; Guglielmini PF; Veccia A; Maruzzo M; Rossi E; Grossi F; Casadei C; Ficorella C; Montesarchio V; Verderame F; Rizzo M; Guaitoli G; Fratino L; Accettura C; Mencoboni M; Zustovich F; Baldessari C; Cinieri S; Camerini A; Laera L; Sorarù M; Zucali PA; Guadalupi V; Leonardi F; Tiseo M; Tognetto M; Di Costanzo F; Pinto C; Negrini G; Russo A; Migliorino MR; Filetti M; Buti S;
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016723
[TBL] [Abstract][Full Text] [Related]
3. Influenza Vaccination in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Tsiakos K; Kyriakoulis KG; Kollias A; Kyriakoulis IG; Poulakou G; Syrigos K
J Immunother; 2022 Jul-Aug 01; 45(6):291-298. PubMed ID: 35639000
[TBL] [Abstract][Full Text] [Related]
4. Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Chong CR; Park VJ; Cohen B; Postow MA; Wolchok JD; Kamboj M
Clin Infect Dis; 2020 Jan; 70(2):193-199. PubMed ID: 30874791
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study.
Mandala M; Lorigan P; De Luca M; Bianchetti A; Merelli B; Bettini AC; Bonomi L; Nahm S; Vitale MG; Negrini G; Di Croce A; Ascierto PA; Rulli E; Tondini CA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593827
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of influenza vaccine in patients with lung cancer receiving immune checkpoint inhibitors: A single-center prospective cohort study.
Nakashima K; Homma Y; Taniguchi J; Kubota N; Otsuki A; Ito H; Otsuka Y; Kondo K; Ohfuji S; Fukushima W; Hirota Y
J Infect Chemother; 2023 Nov; 29(11):1038-1045. PubMed ID: 37481070
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Ruiz JI; Lopez-Olivo MA; Geng Y; Suarez-Almazor ME
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746512
[TBL] [Abstract][Full Text] [Related]
8. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study.
Mei Q; Hu G; Yang Y; Liu B; Yin J; Li M; Huang Q; Tang X; Böhner A; Bryant A; Kurts C; Yuan X; Li J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264438
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Keam B; Kang CK; Jun KI; Moon SM; Suh KJ; Lee DW; Ock CY; Kim M; Choi Y; Lim Y; Lee KH; Kim SH; Kim TM; Kim TY; Oh DY; Kim DW; Im SA; Lee JS; Kim ES; Kim HB; Kim NJ; Kim YJ; Park WB; Oh MD
Clin Infect Dis; 2020 Jul; 71(2):422-425. PubMed ID: 31680143
[TBL] [Abstract][Full Text] [Related]
10. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events.
Wijn DH; Groeneveld GH; Vollaard AM; Muller M; Wallinga J; Gelderblom H; Smit EF
Eur J Cancer; 2018 Nov; 104():182-187. PubMed ID: 30368069
[TBL] [Abstract][Full Text] [Related]
11. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
[TBL] [Abstract][Full Text] [Related]
12. Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors.
Gwynn ME; DeRemer DL; Saunders KM; Parikh J; Bollag RJ; Clemmons AB
J Oncol Pharm Pract; 2020 Apr; 26(3):647-654. PubMed ID: 31474214
[TBL] [Abstract][Full Text] [Related]
13. Serological response and immune-related adverse events following COVID-19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Wang Y; Chen D; Pan Y; Li H; Zhao W; Lu T; Kong W; Ding M; Wang X; Zhang G
Rev Med Virol; 2024 Jan; 34(1):e2495. PubMed ID: 38017632
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors.
Yang Y; Xu G
Cell Death Dis; 2023 Jun; 14(6):390. PubMed ID: 37391394
[TBL] [Abstract][Full Text] [Related]
15. Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan.
Hibino M; Uryu K; Takeda T; Kunimatsu Y; Shiotsu S; Uchino J; Hirai S; Yamada T; Okada A; Hasegawa Y; Hiranuma O; Chihara Y; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T; Takayama K
J Thorac Oncol; 2022 Aug; 17(8):1002-1013. PubMed ID: 35752437
[TBL] [Abstract][Full Text] [Related]
16. Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients.
Bersanelli M; Scala S; Affanni P; Veronesi L; Colucci ME; Banna GL; Cortellini A; Liotta F
Immunotherapy; 2020 Feb; 12(2):105-110. PubMed ID: 32046555
[No Abstract] [Full Text] [Related]
17. Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer.
Piening A; Ebert E; Khojandi N; Alspach E; Teague RM
Front Immunol; 2022; 13():1022732. PubMed ID: 36582225
[TBL] [Abstract][Full Text] [Related]
18. The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.
Grima AA; Kwong JC; Richard L; Reid J; Raphael J; Basta NE; Carignan A; Top KA; Brousseau N; Blanchette PS; Sundaram ME;
Vaccine; 2024 Mar; 42(7):1498-1505. PubMed ID: 38341288
[TBL] [Abstract][Full Text] [Related]
19. Vaccination and Immune Checkpoint Inhibitors: Does Vaccination Increase the Risk of Immune-related Adverse Events? A Systematic Review of Literature.
Desage AL; Bouleftour W; Rivoirard R; Magne N; Collard O; Fournel P; Tissot C
Am J Clin Oncol; 2021 Mar; 44(3):109-113. PubMed ID: 33350679
[TBL] [Abstract][Full Text] [Related]
20. Cell-Mediated Immunogenicity of Influenza Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors.
Kang CK; Kim HR; Song KH; Keam B; Choi SJ; Choe PG; Kim ES; Kim NJ; Kim YJ; Park WB; Kim HB; Oh MD
J Infect Dis; 2020 Nov; 222(11):1902-1909. PubMed ID: 32479600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
